American Society of Clinical Oncology (ASCO)

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Behavioral Interventions Demonstrate Improved Long-Term Adherence to Adjuvant Endocrine Therapy Among Women with HR-Positive Breast Cancer

ASCO 2021 – Breast Cancer

Many women with HR-positive breast cancer contend with emotional distress during prolonged adjuvant endocrine therapy. Behavioral interventions show promise as effective strategies to reduce stress and improve adherence to therapy. Read More ›

Wrap-Up

Necessity for Increased Screening for Genetic Testing Eligibility Among Long-Term Breast Cancer Survivors

ASCO 2021 – Breast Cancer: Wrap-Up

Breast cancer survivors may test positive for pathogenic germline variants 10 years after their original diagnosis. Germline genetic testing may be an important tool for managing care. Read More ›

Need for Improved Access to Cancer Screening Tools for Minorities with Socioeconomic Barriers to Medical Care

ASCO 2021 – Breast Cancer

Low socioeconomic status is associated with delayed access to age-appropriate cancer screenings due to cost of care. Read More ›

Novel and Clinically Relevant Measure of Perceived Fatigability Reveals Benefit of Exercise in Breast Cancer Survivors

ASCO 2021 – Breast Cancer

Perceived fatigability may be a more clinically relevant measurement of the effectiveness of exercise intervention on reducing fatigue among survivors of breast cancer. Read More ›

Association of Stage of Breast Cancer Diagnosis and Socioeconomic Status in French Women

ASCO 2021 – Breast Cancer

Advanced-stage diagnosis of breast cancer is associated with deprived-rural socioeconomic status in French women. Read More ›

Alpelisib Overcomes Resistance to CDK4/6 Inhibitors in HR-Positive/HER2-Negative Advanced Breast Cancer Patients

ASCO 2021 – Breast Cancer

Alpelisib may overcome resistance to CDK4/6 inhibitors in HR-positive/HER2-negative advanced breast cancer patients with shorter exposure to prior CDK4/6 inhibitor treatment. Read More ›

Demographic and Clinical Factors Among Women with Breast Cancer Create a Gap Between Referrals and Completion of Genetic Counseling and Testing

ASCO 2021 – Breast Cancer

Lack of genetic counseling referrals in women diagnosed with breast cancer contribute to a gap between the need for and completion of genetic testing, reducing access to more personalized therapies for these patients. Read More ›

Effect of Alpelisib on Progression-Free Survival in Breast Cancer Patients with PIK3CA Mutations in the Real-World Setting

ASCO 2021 – Breast Cancer

Alpelisib activity improves real-world progression-free survival in breast cancer patients with PIK3CA mutations when used in combination with fulvestrant compared with fulvestrant alone. Read More ›

Trends in Male Breast Cancer Survival Rates from 1988 to 2017

ASCO 2021 – Breast Cancer

Research indicates no significant improvement in breast cancer–specific survival in male breast cancer in the past 30 years. Read More ›

Association of Poor Prognostic Understanding and Discordance Between Older Patients with Advanced Cancer and Oncologists

ASCO 2021 – Breast Cancer

Prognostic understanding may be associated with hospitalization or hospice use depending on how patients were queried about their prognosis and whether oncologists’ estimates were considered. Read More ›

American Society of Clinical Oncology (ASCO)

Page 6 of 31